Document is current

Any future updates will be listed below

Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

Crossref DOI link: https://doi.org/10.1007/s00520-016-3304-1

Published Online: 2016-06-22

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark